This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Biomarker Research Open Access 20 December 2021
-
Recent updates for antibody therapy for acute lymphoblastic leukemia
Experimental Hematology & Oncology Open Access 27 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA. 1980;77:1588–92.
Katz F, Povey S, Parkar M, Schneider C, Sutherland R, Stanley K, et al. Chromosome assignment of monoclonal antibody-defined determinants on human leukemic cells. Eur J Immunol. 1983;13:1008–13.
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–8.
Damle R. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.
Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124:414–20.
Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone MG, et al. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest. 1994;71:853–61.
Parry-Jones N, Matutes E, Morilla R, Brito-Babapulle V, Wotherspoon A, Swansbury GJ, et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol. 2007;137:117–24.
Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 2000;24:153–9.
Marinov J, Koubek K, Stary J. Immunophenotypic significance of the lymphoid Cd38 antigen in myeloid blood malignancies. Neoplasma. 1993;40:355–8.
Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.
Wang L, Wang H, Li PF, Lu Y, Xia ZJ, Huang HQ, et al. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Ann Hematol. 2015;94:1381–8.
van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood. 2012;120:2376–89.
Doshi P, Sasser AK, Axel A, Lammerts van Bueren J. Daratumumab treatment alone or in combination with vincristine results in the inhibition of tumor growth and long term survival in preclinical models of acute lymphocytic leukemia. Haematologica. 2014;99:P109.
KL Bride, T Vincent, S-YL Im, T Fuller, T Ryan, DM Barrett, et al. Abstract 2642: preclinical efficacy of daratumumab in acute lymphoblastic leukemia. AACR Annual Meeting 2017; April 1–5, 2017; Washington, DC.
Bride KL, Vincent TL, Im S, Barrett DM, Hermiston ML, Horton TM, et al. Targetting CD 38 in T cell acute lymphoblastic leukemia. Blood. 2017;130(Suppl 1):3888.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD 38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–94.
Trial evaluating the efficacy and safety of Daratumumab in subjects with relapsed/refractory B-cell or T-cell precursor acute lymphoblastic leukemia (ALL). https://clinicaltrials.gov/ct2/show/NCT03207542. Accessed 24 Feb 2018.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bonda, A., Punatar, S., Gokarn, A. et al. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy?. Bone Marrow Transplant 53, 1487–1489 (2018). https://doi.org/10.1038/s41409-018-0222-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0222-5
This article is cited by
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Biomarker Research (2021)
-
Recent updates for antibody therapy for acute lymphoblastic leukemia
Experimental Hematology & Oncology (2020)
-
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
Leukemia (2020)